RORγt Inverse agonist 6
Modify Date: 2024-01-22 14:32:37
RORγt Inverse agonist 6 structure
|
Common Name | RORγt Inverse agonist 6 | ||
|---|---|---|---|---|
| CAS Number | 1887161-80-9 | Molecular Weight | 565.02 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H29ClN6O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RORγt Inverse agonist 6RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the treatment of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1]. |
| Name | RORγt Inverse agonist 6 |
|---|
| Description | RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the treatment of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1]. |
|---|---|
| Related Catalog | |
| In Vivo | RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1]. RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng•h/mL at 1 mg/kg, po)[1]. RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1]. Animal Model: Mice[1]. Dosage: 30 mg/kg. Administration: Orally twice: at 30 min before and 8 h after IL-23 administration. Result: Inhibited the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose. |
| References |
| Molecular Formula | C28H29ClN6O5 |
|---|---|
| Molecular Weight | 565.02 |